FACT SHEET v1.0 · May 2026
Cancer Series

Active surveillance: the program at a glance

You chose to watch your prostate cancer closely instead of treating it right away. For low-risk prostate cancer, that is the recommended care in the major guidelines. For the full story, see the Active Surveillance Patient Guide.

15 years
Long-term data shows watching does not raise the chance of dying of prostate cancer for low-risk men.
50 to 70
Out of 100 men on surveillance for low-risk cancer never need treatment over 10 to 15 years.
Most
Men who do switch to treatment later are still cured.

Active surveillance is a treatment

You will hear, often from family and friends, that watching a cancer is dangerous. For the kind of prostate cancer you have, the strongest data we have says the opposite when you stay on the program.

Your typical first two years
Month 0Diagnosis. Baseline MRI if not already done. Tumor gene test in some cases.
Month 6PSA blood test. Brief visit.
Month 6 to 12Confirmatory biopsy, often with MRI guidance. Makes sure the first biopsy did not miss higher-grade cancer.
Month 12PSA, exam, visit.
Month 18PSA.
Month 24PSA, exam, MRI, visit.
Year 3 and onPSA every 6 months. Exam and MRI every 12 to 18 months. Biopsy when a result triggers it.

Staying on schedule

Missing visits is the most common preventable failure of active surveillance. If a PSA, MRI, or biopsy slips off your calendar, call and reschedule it. Prostate cancer cannot be felt, so missed tests can hide a change for years. If you want to stop surveillance, do it with your urologist.

What would change the plan
Grade goes up
A repeat biopsy shows a higher grade. The single most important reason to switch.
Volume goes up
More biopsy cores show cancer, or a single core has much more cancer than before.
MRI changes
A new lesion appears, or a known one grows. A targeted biopsy is the usual next step.
PSA pattern shifts
A PSA that climbs in a steady, unexplained way. Single high values are common and often mean nothing on their own.
Genetic signal changes
A high tumor gene score, or a worse score on a later test, can prompt earlier treatment.
You change your mind
A legitimate trigger. Choosing treatment after stable surveillance is a respected decision.
Living with the worry between visits

Worry belongs on the side-effect list for surveillance. Anxiety builds in the week before a PSA, MRI, or biopsy. Some call it scanxiety. About 5 to 10 in 100 men leave the program for worry alone, even when their tests stay steady.

Keep the schedule visible

Know exactly when the next PSA, MRI, and visit are set. Having those dates in front of you is steadying on its own.

Know your trigger plan

Knowing in advance what would change the plan takes the "is today's number the bad one" loop out of your head.

Tell someone about the worry

Your urologist and your partner are both fair places to start. Many programs also have a nurse navigator or social worker whose job is partly this.

Brief therapy works

A short course of cognitive behavioral therapy fits health worry well. Anxiety medicine is sometimes the right call too.

Do not check your own PSA

Some men order their own tests between visits and watch the number every day. This almost never helps.

Talk with another man on surveillance

Hearing from someone 5 or 10 years into the program often helps more than any statistic.

If the plan does change

About 30 to 50 in 100 men on surveillance for low-risk cancer eventually move to treatment. That move is a planned part of the program. The data say most men who switch are still cured, and the years you spent on surveillance were years without surgical or radiation side effects.

Telling family and friends
  • Lead with the plan, not the diagnosis. "I have a slow-growing prostate cancer that the major guidelines say should be watched, not treated right now. Here is what watching looks like."
  • Name the program out loud. PSA every 6 months. MRI every year or so. Planned biopsy. A clear list of reasons to switch.
  • Borrow the data. "A 15-year trial showed that for the kind of cancer I have, watching has the same chance of dying of prostate cancer as upfront treatment, with far fewer urinary and sexual side effects."
  • Pick one person to be your full audience. A partner, an adult child, a sibling. Most other people only need the headline.
  • Bring your partner to a visit. Let your urologist explain the plan in their own words. Agree on what counts as a check-in moment.
Questions to bring to your next visit
  • What is my risk group, and what does that mean for my plan?
  • When is my next PSA, MRI, and biopsy scheduled?
  • Has a tumor gene test (Decipher) been done, and would it help?
  • Should I be tested for inherited gene changes (BRCA2 and others)?
  • What exactly would change the plan for me?
  • I take finasteride or dutasteride (or plan to start). These cut PSA by about half. How does that change how you read my PSA?

Call your team the same day for

You cannot urinate. You run a fever after a recent biopsy. You have heavy bleeding from the rectum or urethra after a biopsy (a small amount of blood in urine or semen for days to weeks is normal; heavy bleeding is not).

The full guide

It covers who fits the program, the ProtecT 15-year data, and the habits that may help. It also has a table on keeping urinary and sexual function, and what the switch to treatment looks like.